-
-20%
SINOVIAL HL SIR 3.2% 1ML
32.12€
40.00€
- Brand: IBSA FARMACEUTICI ITALIA Srl
- Product Code: 935184527
- EAN: 8033638951026
- Availability: In Stock
- Purchase 3 items for 31.48€ each
- Purchase 4 items for 30.84€ each
- Purchase 5 items for 30.19€ each
Sinovial HL 1ml
3.2% - 16mg (H-HA) + 16mg (L-HA) 1ml
Hyaluronic acid sodium salt
Visco-supplementary device of the joints
1 pre-filled syringe of 1 ml and 2 needles
Sterile - Disposable
DESCRIPTION
The sadistic salt of hyaluronic acid is formed by repeated chains of disaccharide units of N-acetylglucosamine and sodium glucuronate and represents a fundamental component of the synovial fluid, to which it gives the particular viscoelastic properties.
Consisting of a buffered physiological solution of high molecular weight (H-HA) and low molecular weight (L-HA) hyaluronic acid.
The high and low molecular weight hyaluronic acid used in the device is obtained by fermentation and has not undergone chemical modification processes. This results in excellent tolerability.
Furthermore, the HA chains with different molecular weights present in the product, thanks to a specific and patented treatment of the solution, interact with each other, giving the product unique rheological characteristics which allow for the administration of higher concentrations of hyaluronic acid with the same viscosity of the solution.
In vitro studies were carried out to identify any incompatibilities and/or interactions between the product and Platelet Rich Plasma (PRP), used for the intraarticular infiltrative treatment of osteoarthritis.
The results obtained demonstrate that PRP does not modify the rheological behavior of sodium hyaluronate, which therefore retains its viscosupplementation function; moreover, the results of studies conducted on cultures of human mesenchymal stem cells (MSC) differentiated into chondrocytes demonstrate that there is no cellular suffering, an index of toxicity: there is therefore no reason to believe that the biocompatibility of the product is modified by the simultaneous administration of PRP.
The other ingredients of the product are: sodium chloride, sodium phosphate and water for injections.
INDICATED
In case of pain or reduced mobility due to degenerative diseases (arthrosis), post-traumatic injuries and tendinopathies associated with joint disability.
Device for integration of synovial fluid, which allows to restore the physiological and rheological properties of arthritic joints.
By restoring the viscoelastic properties of the synovial fluid, it reduces pain and restores joint and tendon mobility, acting only at the level of the joint where it is injected, without exerting any systemic action.
Treatment can go up to three injections depending on the severity of the joint degeneration.
The opportunity and frequency with which the treatment cycle can be repeated must be evaluated by the doctor for each individual patient, considering in each case the risk/benefit ratio of the treatment.
PRODUCT DESCRIPTION
It comes in the form of a 1.25 ml glass syringe containing 1 ml of solution; The contents of the syringe are sterile and non-pyrogenic.
INSTRUCTION FOR USE
- Carry out 2 infiltrations per cycle 15 days apart from each other.
- Aspirate any articular effusion before proceeding with the injection of the product.
- Pull off the syringe cap paying particular attention to avoid contact with the opening.
- Insert the appropriate needle included in the package (29 G or / 22 G).
- Screw the needle tightly into the Luer-type locking collar of the syringe to ensure a watertight seal and prevent leakage during administration.
- Inject at room temperature and under strictly aseptic conditions.
- Inject only
3.2% - 16mg (H-HA) + 16mg (L-HA) 1ml
Hyaluronic acid sodium salt
Visco-supplementary device of the joints
1 pre-filled syringe of 1 ml and 2 needles
Sterile - Disposable
DESCRIPTION
The sadistic salt of hyaluronic acid is formed by repeated chains of disaccharide units of N-acetylglucosamine and sodium glucuronate and represents a fundamental component of the synovial fluid, to which it gives the particular viscoelastic properties.
Consisting of a buffered physiological solution of high molecular weight (H-HA) and low molecular weight (L-HA) hyaluronic acid.
The high and low molecular weight hyaluronic acid used in the device is obtained by fermentation and has not undergone chemical modification processes. This results in excellent tolerability.
Furthermore, the HA chains with different molecular weights present in the product, thanks to a specific and patented treatment of the solution, interact with each other, giving the product unique rheological characteristics which allow for the administration of higher concentrations of hyaluronic acid with the same viscosity of the solution.
In vitro studies were carried out to identify any incompatibilities and/or interactions between the product and Platelet Rich Plasma (PRP), used for the intraarticular infiltrative treatment of osteoarthritis.
The results obtained demonstrate that PRP does not modify the rheological behavior of sodium hyaluronate, which therefore retains its viscosupplementation function; moreover, the results of studies conducted on cultures of human mesenchymal stem cells (MSC) differentiated into chondrocytes demonstrate that there is no cellular suffering, an index of toxicity: there is therefore no reason to believe that the biocompatibility of the product is modified by the simultaneous administration of PRP.
The other ingredients of the product are: sodium chloride, sodium phosphate and water for injections.
INDICATED
In case of pain or reduced mobility due to degenerative diseases (arthrosis), post-traumatic injuries and tendinopathies associated with joint disability.
Device for integration of synovial fluid, which allows to restore the physiological and rheological properties of arthritic joints.
By restoring the viscoelastic properties of the synovial fluid, it reduces pain and restores joint and tendon mobility, acting only at the level of the joint where it is injected, without exerting any systemic action.
Treatment can go up to three injections depending on the severity of the joint degeneration.
The opportunity and frequency with which the treatment cycle can be repeated must be evaluated by the doctor for each individual patient, considering in each case the risk/benefit ratio of the treatment.
PRODUCT DESCRIPTION
It comes in the form of a 1.25 ml glass syringe containing 1 ml of solution; The contents of the syringe are sterile and non-pyrogenic.
INSTRUCTION FOR USE
- Carry out 2 infiltrations per cycle 15 days apart from each other.
- Aspirate any articular effusion before proceeding with the injection of the product.
- Pull off the syringe cap paying particular attention to avoid contact with the opening.
- Insert the appropriate needle included in the package (29 G or / 22 G).
- Screw the needle tightly into the Luer-type locking collar of the syringe to ensure a watertight seal and prevent leakage during administration.
- Inject at room temperature and under strictly aseptic conditions.
- Inject only